Press releases

Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug...

Boston Scientific Corporation (NYSE: BSX) welcomes final passage today by the United States Senate of "The Food and Drug Administration Safety and...

Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for...

Next-generation wireless remote patient management system enabled for INGENIO™ family of pacemakers is now in use in Europe

Adds first and only commercially available subcutaneous ICD technology that offers new life-saving therapy option to patients at risk of sudden cardiac arrest.

Medical device tax would stifle innovation

Event to be webcast live and will include detailed review of Bronchial Thermoplasty opportunity.

PROMUS Element plus stent system offers physicians the broadest array of Everolimus drug-eluting stent lengths and diameters in the U.S.

Devices projected to have nearly twice the longevity of comparable products

Indication provides new therapeutic option for extraction of difficult-to-manage biliary stones

Seven abstracts and data analyses to be presented May 19 – 22 in San Diego.

Two-year clinical data demonstrate low adverse event rates, including no myocardial infarction or stent thrombosis, for the Boston Scientific 2.25 mm PROMUS Element Platinum Chromium Stent

New self-expanding Nitinol stent offers balance of flexibility and radial strength for enhanced performance in iliac stenting procedures.

Follow-up data from EVOLVE Trial presented at EuroPCR.

Results of REPRISE I study suggest device minimizes aortic regurgitation

Innovative stent designed to treat peripheral vascular lesions for stenoses in arteries above the knee.

Collaboration expected to improve access to imaging data used to treat patients.

Results presented at Heart Rhythm Society from ASA Plavix study evaluating Boston Scientific Left Atrial Appendage Closure Device.

Clinical presentations to include 12-month outcomes data from EVOLVE trial and results of the REPRISE I trial.

Advanced pacemaker platform designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

Clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

A live webcast and replay of the May 8 session will be available. Read more.

Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions.

REPRISE I Trial Results to be Presented at EuroPCR 2012

Fesults “demonstrate continued progress towards improving our future growth profile and in executing our strategic plan," said CEO Hank Kucheman.

Device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 2012 on April 19. Learn how to tune in or watch the replay.

Advanced devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients.

BackStop Gel is a water-soluble polymer that urologists inject into the ureter to form a plug behind the stone, preventing migration of stone fragments of all sizes.

CTAF report supports safety, efficacy and positive health outcomes of bronchial thermoplasty for treatment of patients with severe asthma.

HORIZONS II AMI trial to enroll up to 10,000 patients worldwide, making it the largest randomized trial to study coronary stents in heart attack patients.

Results were presented at the American College of Cardiology Annual Scientific Sessions.

Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012.

Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract.

Data to include two-year results from the PLATINUM Workhorse clinical trial, with follow-up data on PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent.

Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma.

Radiofrequency ablation catheter designed to treat a variety of arrhythmias.

Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest.

Five-year contract extends the existing commercial agreement, promotes continued investments in laser and fiber product development for urologic applications.

Next-generation coronary stent employs innovative alloy designed to improve acute performance.

TELIGEN family of ICDs, designed to treat sudden cardiac death, are the smallest and thinnest high-energy devices available in China.

ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.

A live webcast of the session on February 29, 2012 will be available. Learn how to tune in or watch the replay.

Moody's Investors Service has upgraded the Company's corporate credit rating to an investment grade rating, Baa3, with a stable outlook.

TruePath™ CTO Device designed to facilitate crossing of chronic total occlusions.

A webcast of the February 15, 2012 session will be available. Learn how to tune in live or watch the replay.

Studies published in peer-reviewed medical journals

New device offers excellent flexibility and large size for acquiring tissue samples.

World’s first and only 16-contact percutaneous lead is the latest innovation in company’s comprehensive percutaneous lead portfolio.

“We continue to make progress with new product introductions, cost-saving initiatives and a strengthened presence in emerging markets," said CEO Hank Kucheman.